Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today that Taylor ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

ProstACT Global is trialling a promising new treatment option for prostate cancer, which is the most commonly diagnosed cancer and the second leading cause of cancer-related death for U.S. men. This ...

Using an approach called DNA origami, scientists at Caltech have developed a technique that could lead to cheaper, reusable ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Invivyd (IVVD) announced that Invivyd’s request to expand the existing emergency use authorization for pre-exposure prophylaxis of COVID-19 EUA ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and ...

Learn more about whether Insmed Incorporated or BeiGene, Ltd. is a better investment based on AAII's A+ Investor grades, ...

Learn more about whether AbbVie Inc. or BeiGene, Ltd. is a better investment based on AAII's A+ Investor grades, which ...

Type-1 interferons regulate immune responses and the production of self-reactive antibodies that target red blood cells in a SCD mouse model.